PHATHOM PHARMACEUTICALS INC (PHAT)
Health Care · Gastrointestinal pharmaceutical therapeutics · NASDAQ
Phathom is a commercial-stage biopharmaceutical company commercializing VOQUEZNA, the first US-approved potassium-competitive acid blocker (PCAB) for gastrointestinal diseases including erosive GERD and H. pylori infection.
What PHATHOM PHARMACEUTICALS INC does
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on commercializing novel treatments for gastrointestinal diseases. The company's approved products—VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK—contain vonoprazan, an oral small-molecule potassium-competitive acid blocker (PCAB), a novel class of molecules that block acid secretion in the stomach. VOQUEZNA is the only PCAB currently approved for marketing in the United States. The company has begun U.S. commercialization of VOQUEZNA for treating erosive gastroesophageal reflux disease (Erosive GERD) and Helicobacter pylori infection.
Themes: ["GI disease treatment","GERD / acid reflux therapy","H. pylori infection treatment","Potassium-competitive acid blockers","Commercial-stage biopharmaceutical"]
Fundamentals
- Price$12.16 as of 2026-07-09 close
- Market cap$959M as of 2026-07-10
- 1-year return+33.7% as of 2026-07-09 close
- Net margin-76.8% as of 2026-07-10
- Gross margin+84.9% as of 2026-07-10
- ROE-232.8% as of 2026-07-10
- Debt / equity12.38 as of 2026-07-10
- Revenue growth (YoY)+150.3% as of 2026-07-10
- Beta0.43 as of 2026-07-10
Key risks (from latest filing)
["High unprofitability with net margin of -76.77% and significant accumulated deficit of $1.5 billion; company is dependent on product revenue growth to reach profitability.","Revenue interest financing liability of $347.9 million plus long-term debt of $163.7 million creates substantial debt burden and financial obligations that constrain operational flexibility.","Competitive pressure from established acid-suppressive therapies (proton pump inhibitors) and other GI treatments; VOQUEZNA faces adoption challenges against entrenched standard-of-care medications."]
Competitors & peers
- AstraZeneca (gastroenterology)
- Takeda Pharmaceutical (gastroenterology)
- Pfizer (gastrointestinal products)
- Abbott (diagnostic and therapeutic GI products)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.